Cristina Saura
Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease.
Overview
Cristina Saura led NALA (neratinib plus capecitabine) and is a principal investigator of DESTINY-Breast09, the trial showing trastuzumab deruxtecan plus pertuzumab outperforms the CLEOPATRA regimen first line. She heads breast cancer at Vall d'Hebron, is active in the SOLTI cooperative group, and works on ctDNA and brain-metastasis strategies in HER2-positive disease.
| Title | Journal | Year |
|---|---|---|
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with two or more HER2-directed regimens (NALA) | JCO | 2020 |
| Trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive advanced breast cancer (DESTINY-Breast09) | NEJM | 2025 |
Pages like this
not linked directly; found by shared links- PersonIan E. Krop
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, her2, adc.
- PersonShanu Modi
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc.
- PersonHelena Earl
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- PersonSandra M. Swain
Shares HER2, HER2-positive breast cancer and the tags breast, her2.
- PersonJoaquín Arribas
Shares Vall d'Hebron University Hospital / VHIO, HER2, HER2-positive breast cancer.
- PersonAditya Bardia
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
- PersonJavier Cortés
Shares DESTINY-Breast09, Vall d'Hebron University Hospital / VHIO, Trastuzumab deruxtecan, HER2.